The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution
暂无分享,去创建一个
Masaru Furuta | Masahiro Yasunaga | Yasuhiro Matsumura | Yoshiyuki Yamamoto | Y. Matsumura | M. Yasunaga | M. Furuta | Y. Koga | K. Ogata | Koretsugu Ogata | Yoshikatsu Koga | Yoshiyuki Yamamoto | Misato Takigahira | M. Takigahira
[1] Y. Matsumura. Cancer stromal targeting (CAST) therapy. , 2012, Advanced drug delivery reviews.
[2] D. Cunningham,et al. Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours , 2013, The British journal of surgery.
[3] K. Kataoka,et al. Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles , 2009, Cancer science.
[4] D. Ettinger,et al. Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Kristina Schwamborn,et al. Molecular imaging by mass spectrometry — looking beyond classical histology , 2010, Nature Reviews Cancer.
[6] Bernhard Spengler,et al. Mass spectrometry imaging with high resolution in mass and space , 2013, Histochemistry and Cell Biology.
[7] Alnawaz Rehemtulla,et al. PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. , 2008, Current computer-aided drug design.
[8] K. Kataoka,et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel , 2005, British Journal of Cancer.
[9] E K Rowinsky,et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Cain,et al. The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Syrigos,et al. Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer , 2012, Therapeutic advances in medical oncology.
[12] Takahiro Hayasaka,et al. Development of imaging mass spectrometry. , 2012, Biological & pharmaceutical bulletin.
[13] M. R. Groseclose,et al. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. , 2011, Bioanalysis.
[14] W. Pao,et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. , 2013, AJR. American journal of roentgenology.
[15] Michelle L. Reyzer,et al. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems , 2007, Nature Methods.
[16] M. Suematsu,et al. Visualization of volatile substances in different organelles with an atmospheric-pressure mass microscope. , 2009, Analytical chemistry.
[17] L. Pusztai,et al. Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer , 2013, Clinical Cancer Research.
[18] H. Ueno,et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation , 2007, British Journal of Cancer.
[19] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[20] O. Ovchinnikova,et al. Laser microdissection and atmospheric pressure chemical ionization mass spectrometry coupled for multimodal imaging. , 2013, Rapid communications in mass spectrometry : RCM.
[21] Brian Samuels,et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[23] P. Workman,et al. Discovering novel chemotherapeutic drugs for the third millennium. , 1999, European journal of cancer.
[24] Joe W. Gray,et al. Translating insights from the cancer genome into clinical practice , 2008, Nature.
[25] Ruth Duncan,et al. Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.
[26] T. Yoshikawa,et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer , 2012, Investigational New Drugs.